NCT04891679

Brief Summary

AIM: To evaluate effectiveness and safety of titrated oral misoprostol solution (OMS) in comparison with static-dose oral misoprostol solution for induction of labor at term. Women with singleton live pregnancy at term without any complications who were admitted in labor room for induction of labor were enrolled. Study involves allocation of selected women in two groups randomly and use of either titrated or static oral misoprostol dose regimen to induce labor. Possible benefits included rapid induction of labor with oral drug regimen which is easier to comply as compared to vaginal regimens. Women were at risk of all the complications associated with induction of labor like labor abnormalities, risk of cesarean section, non reassuring fetal status.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
264

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2017

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2018

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

May 13, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 18, 2021

Completed
Last Updated

May 18, 2021

Status Verified

May 1, 2021

Enrollment Period

12 months

First QC Date

May 13, 2021

Last Update Submit

May 13, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Interval between induction and delivery

    The time taken from induction of labor to delivery measured as 1\) \<12 hours 2) 12-24 hours 3) 24-48 hours 4) \>48 hours

    From first dose of oral misoprostol solution (titrated/static) to childbirth; upto 5 days

Secondary Outcomes (9)

  • Mean change in modified Bishop's score

    From first dose of oral misoprostol solution to childbirth (intrapartum); upto 5 days

  • Number of misoprostol doses

    From first dose of oral misoprostol solution to childbirth (intrapartum); upto 5 days

  • Time taken to give required doses

    From first dose of oral misoprostol solution to childbirth (intrapartum); upto 5 days

  • Total misoprostol dosage

    From first dose of oral misoprostol solution to childbirth (intrapartum); upto 5 days

  • Mode of delivery

    Upto 5 days from first dose of oral misoprostol solution

  • +4 more secondary outcomes

Study Arms (2)

Group A (Titrated OMS)

ACTIVE COMPARATOR

Titrated oral misoprostol solution

Drug: Oral misoprostol solution (OMS)

Group B (Static OMS)

ACTIVE COMPARATOR

Static oral misoprostol solution

Drug: Oral misoprostol solution (OMS)

Interventions

Based on the WHO labor induction recommendation, and for the purpose of achieving precise oral misoprostol dosage, one misoprostol tablet (200 mcg) was pulverized and dissolved into 200 ml water.90 Thus 1ml of solution had 1mcg of misoprostol. This misoprostol solution could be preserved at room temperature and remained active for 24 hours. Hourly titrated oral misoprostol solution was given to group A as described by Wang X et al, 2016 as described below. 0 hour= 20ml 1. hour= 20ml 2. hour= 30ml 3. hour= 30ml 4. hour= 30ml 5. hour= 40ml 6.5 hour= 50ml 8.5 hour= 60ml 10.5 hour=60ml Group B received 25 mcg (25 ml) oral misoprostol solution every 2 hours for a maximum of 12 doses or until the onset of regular uterine activity.

Group A (Titrated OMS)Group B (Static OMS)

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsPregnant females were enrolled for induction of labor in the study.
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Singleton live pregnancy;
  • ≥37 weeks gestation;
  • Cephalic presentation;
  • Reassuring fetal heart rate;
  • Modified Bishop'score

You may not qualify if:

  • Hypersensitivity to misoprostol;
  • Uterine scar due to previous cesarean section or other uterine surgery;
  • Grand multipara;
  • Multiple gestations;
  • High risk pregnanacies • preeeclampsia with severe features • significant maternal cardiac,renal, liver disease
  • Any contraindication to induction and vaginal delivery e.g. cephalopelvic disproportion, malpresentation, fetal compromise and ante partum hemorrhage
  • Intrauterine fetal demise

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Christian Medical College and Hospital

Ludhiana, Punjab, 141008, India

Location

Related Publications (2)

  • Rouzi AA, Alsahly N, Alamoudi R, Almansouri N, Alsinani N, Alkafy S, Rozzah R, Abduljabbar H. Randomized clinical trial between hourly titrated and 2 hourly static oral misoprostol solution for induction of labor. Am J Obstet Gynecol. 2017 Apr;216(4):405.e1-405.e6. doi: 10.1016/j.ajog.2016.11.1054. Epub 2016 Dec 14.

    PMID: 27986461BACKGROUND
  • Aduloju OP, Ipinnimo OM, Aduloju T. Oral misoprostol for induction of labor at term: a randomized controlled trial of hourly titrated and 2 hourly static oral misoprostol solution. J Matern Fetal Neonatal Med. 2021 Feb;34(4):493-499. doi: 10.1080/14767058.2019.1610378. Epub 2019 Apr 29.

    PMID: 31006282BACKGROUND

Study Officials

  • SUNITA GOYAL, MBBS, MD

    Department of obstetrics and gynecology, Christian Medical College and hospital, Ludhiana

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
Women were randomized (1:1) into the treatment groups A) Titrated-dose OMS group B) Static dose OMS group; using computer generated number sequence. Allocation concealment was carried out by using opaque envelopes that were distributed by the obstetrics nurse. Whereas study investigators and attending care teams were aware of the allocated arm, patients were kept blinded to the allocation. Study investigators and outcome assessors could not be blinded as the data collection and analysis included outcome measures like timing of oral misoprostol solution doses.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Single center interventional single-blinded randomised controlled trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Resident, Department of obstetrics and gynecology

Study Record Dates

First Submitted

May 13, 2021

First Posted

May 18, 2021

Study Start

December 1, 2017

Primary Completion

November 30, 2018

Study Completion

November 30, 2018

Last Updated

May 18, 2021

Record last verified: 2021-05

Data Sharing

IPD Sharing
Will share

IPD that underlie the results reported in the study, after deidentification (text, tables, figures and appendices) will be shared in the excel sheet format.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
Data will be available beginning immediately and ending 36 months following article publication.
Access Criteria
Anyone who wishes to access the data for any purpose. Link will be made available at a later date.

Available IPD Datasets

Informed Consent Form (PATIENT INFORMATION SHEET)Access
Study Protocol (STUDY PROTOCOL)Access

Locations